# Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

> **NCT04831320** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 46 (actual)

## Conditions studied

- Metastatic Head-and-neck Squamous-cell Carcinoma

## Interventions

- **DRUG:** nab-paclitaxel
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04831320
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-28
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-01-31
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04831320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04831320, "Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04831320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*